Moolec ScienceMLEC -5.81%46 Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus rates MLEC with a GF Score™ of 46/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,201 Biotechnology companies, Moolec Science ranks worse than 83263.86% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Moolec Science's annualized net income for the quarter that ended in Dec. 2025 was $137.9 Mil. Moolec Science's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $-102.9 Mil. Therefore, Moolec Science's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was Negative Tangible Equity%.
The historical rank and industry rank for Moolec Science's Return-on-Tangible-Equity or its related term are showing as below:
MLEC's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.4 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Moolec Science Return-on-Tangible-Equity Related Terms
Moolec Science Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Moolec Science's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs GNPX, ADIL, APVO: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Moolec Science's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Moolec Science's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Moolec Science (MLEC) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #999999 out of 1201 companies in the Biotechnology industry.
Is Moolec Science's Return-on-Tangible-Equity too high?
Moolec Science's current Return-on-Tangible-Equity is Negative Tangible Equity%. Based on the distribution chart, Moolec Science ranks #999999 out of 1201 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's Return-on-Tangible-Equity compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #999999 out of 1201 companies for Return-on-Tangible-Equity. This places Moolec Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Moolec Science and its competitors. Moolec Science's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.62 — trading 91% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Moolec Science (MLEC), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.62 is trading 91% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
